The Ministry recognizes the innovation present in Tetraneutron’s research and developments within the field of Alzheimer’s disease. Additionally, Tetraneuron advance in the regulatory roadmap with its innovative therapy.
Madrid, September 7, 2021.- Tetraneuron, a biotech company developing a multifactorial genetic therapy against the Alzheimer’s disease, announced the obtention of the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation. Consequently, the company has been registered in the official public register of Innovative SMEs.
By awarding this distinction, whose objective is to reward and highlight SMEs activities in regards to R&D and innovation, the Ministry is officially recognizing the innovative and pioneering nature of Tetraneutron’s research in the field of Alzheimer’s disease.
As a resident company of Johnson & Johnson Innovation, JLABS, Tetraneuron is developing an advanced therapy for Alzheimer’s disease through a therapeutic approach based on E2F4, a protein involved in the origin of the pathogenesis of this complicated disease. With encouraging preclinical results, the company is pursuing a multifactorial approach to Alzheimer’s through gene therapy that is expected to slow the progression of a disease, that currently affects more than 50 million people around the world.
Consequently, the obtention of the INNOVATIVE SME seal by Tetraneuron is a strong support for its roadmap, which has clinical trial as a short-term objective.
For more information,
Mari Carmen Álvarez (firstname.lastname@example.org)
David Mor (email@example.com)